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Abstract: Physical activity (PA) is a factor that may have an influence on the symptoms of Parkinson’s
disease (PD). The aim of this study was to identify the potential determinants of spontaneous PA in a
PD patient group. A total of 134 PD patients aged 65.2 ± 9.2 years with a Hoehn–Yahr scale score ≤4
and a Mini Mental State Examination (MMSE) score ≥24 were examined. For the study’s purposes,
the authors analyzed age, sex, education, history of PD, dopaminergic treatment, the severity of
PD symptoms using Unified Parkinson’s Disease Rating Scale (UPDRS), and Hoehn–Yahr scale.
Additionally, all participants were evaluated through a set of scales for specific neuropsychiatric
symptoms including depression, anxiety, apathy, fatigue, and sleep disorders. A linear regression
analysis was used with backward elimination. In the total explanatory model, for 12% of the variability
in activity (R2 = 0.125; F(16.133) = 2.185; p < 0.01), the significant predictor was starting therapy
with the dopamine agonist (DA) (β= 0.420; t= 4.068; p = 0.000), which was associated with a longer
duration of moderate PA. In the total explanatory model, for more than 13% of the variance in
time spent sitting (R2 = 0.135; F(16.130) = 2.267; p < 0.01), the significant predictors were secondary
education and the results of the UPDRS. The patients with secondary and vocational education, those
starting treatment with DA and those with a less severe degree of Parkinson’s symptoms (UPDRS),
spent less time sitting in a day. It is possible to identify determinants of spontaneous PA. It may
elucidate consequences in terms of influence on modifiable conditions of PA and the proper approach
to patients with unmodifiable PA factors.
Keywords: Parkinson’s disease; physical activity; sedentary way; non-motor symptoms; apathy;
dopaminergic therapy
1. Introduction
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases and the most
common form of parkinsonian syndrome. It affects 1% of people older than 60 years of age and 4% of
people older than 80 years of age [1]. The main symptoms of PD primarily result from a dopaminergic
deficit and include bradykinesia, tremors, rigidity, and postural instability, but in the course of PD, there
are also numerous non-motor symptoms including neuropsychiatric, autonomic and gastrointestinal
aspects [2].
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The evidence collected thus far indicates that one of the important non-pharmacological
interventions in the course of PD is the physical activity (PA) of the patients [3–5]. Even cortical activity
tends to increase with PA like walking and balance tasks in older and PD groups compared to baseline
conditions (sitting/standing) or controls [6]. The beneficial effects of PA on the central nervous system
(CNS) are associated with many factors, including neurotrophic factors and, above all, the cerebral
nerve growth factor and attributable neuroplasticity [7,8]. While these results are promising, current
PD treatments are aimed at addressing motor symptoms, and there is no therapy focused on modifying
the course of the disease [9].
So far, the literature has not elucidated the determinants of physical activity or inactivity in
patients with PD. The present study analyzes the impact of sociodemographic factors, clinical features
of the disease, and treatment on the time patients spend participating in spontaneous PA.
2. Material and Methods
2.1. Subjects
A total of 134 PD patients aged 65.2 ± 9.2 years (61 women, 73 men), treated at the outpatient
Neurology Clinic of the Silesian Medical University in Katowice, were examined. The study
was approved by the Bioethics Committee of the Academy of Physical Education in Katowice.
All participants signed the informed consent form. PD was diagnosed based on the principles of the
United Kingdom Parkinson’s Disease Society Brain Bank. All other diseases in stable patients were
under medical supervision. Figure 1 shows a flow chart of the participants’ recruitment.
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Figure 1. Flow-chart of patient selection.
In the examined group, the basic treatment was levodopa followed, in the frequency of use, by a
DA (ropinirole or piribedil) The levodopa equivalent daily dose (LED) was calculated on the basis of
the conversion ratios accepted based on the literature review [10]. The participants were patients with
Hoehn–Yahr stage [11] ≤4 with a Mini-Mental State Examination (MMSE) score [12] ≥24 points and
with a duration of symptoms and dopamine replacement therapy (DRT) ≥0.5 year. Characteristics of
the respondents are presented in Table 1.
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Table 1. Characteristics of the subjects.
Variable M (SD)
Sex: Women/Men (n) 61/73
Age (years) 65.2 (9.2)
Place of residence (%)
A city with over 100 thousand inhabitants.
















Accompanying conditions (%) 84.3




The duration of the disease (years) 7.3 (4.2)
Hoehn–Yahr scale (degrees) 2 (0.6)
Time to start treatment (years) 1.4 (1.5)
Daily levodopa equivalent dose—LED (mg) 755.4 (418.7)
Levodopa/dopaminergic agonist (%) 96/52
EOPD, early onset Parkinson’s disease; MOPD, middle age onset Parkinson’s disease; LOPD, late onset
Parkinson’s disease.
2.2. Methods
The study used a diagnostic survey with an authorial questionnaire for the purpose of gathering
information on demographics, the clinical picture of PD, concomitant diseases, and treatment of the
PD patient. The questionnaire was verified in terms of accuracy and reliability in the pilot studies
preceding the main study.
The severity of PD symptoms was evaluated using the Unified Parkinson’s Disease Rating Scale
(UPDRS) scale and the Hoehn–Yahr scale [11]. For mental performance, the MMSE was used [12].
PA was assessed using the International Physical Activity Questionnaire (IPAQ) [13] and the Minnesota
Leisure Time Physical Activity Questionnaire (MLTPAQ) [14]. The questionnaires concerning activity
were conducted by the researcher and covered a typical week of the subject’s life in March and
November [15]. For the assessment of non-motor symptoms (NMS), the following evaluations were
used: depression and anxiety—the Beck Depression Inventory (BDI) [16] and the Hospital Anxiety
and Depression Scale (HADS) [17], apathy—the Apathy Scale (AS) [18], fatigue—the Parkinson’s
Fatigue Scale (PFS−16) [19,20], sleep disturbances—the Pittsburgh Sleep Quality Ratio (PSQI) [21,22],
and excessive daytime sleepiness—the Epworth Sleepiness Scale (ESS) [22].
For the analysis of PA, the data coming from IPAQ [13] and MLTPAQ [14] concerning the type of
PA undertaken based on the level of difficulty (light, moderate, average), the duration of participation
(hours/minutes), and the frequency during the week (number of days) were used.
To assess the results, the following operationalization of data concerning PA was conducted:
The index of time of moderate weekly activity was calculated (ITMWA), which was established by
the following formula: ITMWA = (average time of moderate physical activity from the MLTPAQ
questionnaire + average time of moderate weekly activity from the IPAQ questionnaire)/2. On the
basis of an empirical percentile division of the results obtained, the patients were divided into two
groups: the 33% least active (ITMWA < 45 min a week) and the 33% most active (ITMWA > 2.5 h a
week), which constituted the basis to characterize inactive and active patients.
Moderate weekly activity (ITMWA), which is calculated using the result of MLTPAQ and IPAQ,
is an author’s concept developed for this work. In previous pilot studies, this parameter was verified
by the method of competent judges used verified by Kendall test [23].
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3. Results
The physically “inactive” PD patient group (PI-G), compared to the physically “active” PD patient
group (PA-G), was characterized by a longer duration of the disease (8.2 ± 4.2 vs. 6.3 ± 4.0; p < 0.01)
and less frequent treatment initiation with dopaminergic receptor agonist (DA) (1.9% (n = 1) vs. 21.8%
(n = 12); p < 0.01). In addition, the PI-G had greater difficulties performing the activities of daily living
(ADLs) assessed by UPDRS II (9.2 ± 5.5 vs. 7.0 ± 5.7; p < 0.05), and the PI-G more often suffered from
apathy (15.9 ± 5.6 vs. 13.2 ± 5.4; 63.5% (n = 33) vs. 49.1% (n = 27); p < 0.05). The other analyzed
factors did not reveal statistically significant differences between the PA-G and PI-G. The results of the
assessment of all the factors listed using methodology tools are presented in Table 2.
Table 2. Characteristics and results of the physically active and physically inactive subjects.
Variable PA-G (n = 55) PI-G (n = 53) p Value
Age (years) 66.3 ± 8.1 65.5 ± 10.0 0.516 1
Sex
(W—women, M—Men)
W—45.5% (n = 25
M—54.5% (n = 30)
W—47.2% (n = 25)
M—52.8% (n = 28) 0.858
2
The duration of the disease (years) 6.3 ± 4.0 8.2 ± 4.2 p < 0.01 1
Age of onset of (years) 65.4 ±8.1 66.3 ±10.0 0.622 1
UPDRS I (points) 1.3 ± 1.9 1.6 ± 1.4 0.405 1
UPDRS II (points) 7.0 ± 5.7 9.2 ± 5.5 p < 0.05 1
UPDRS III (points) 24.9 ± 12.5 27.1 ± 13.0 0.246 1
UPDRS IV (points) 1.8 ± 1.7 2.3 ± 2.8 0.381 1
Hoehn–Yahr scale (degree) 2.2 ± 0.6 2.4 ± 0.6 0.055 1
Dyskinesia (%) 20.0 (n = 11) 24.5 (n = 13) 0.218
Motor fluctuation (%) 38.2 (n = 21) 45.3 (n = 24) 0.946
Treatment: levodopa/DA (%) 96.4 (n = 53) 98.1 (n = 52) 0.580 2
Start of treatment with levodopa (%) 74.5 (n = 41) 83.0 (n = 44) 0.282 2
Start of treatment with DA (%) 21.8 (n = 12) 1.9 (n = 1) p < 0.01 2
Time to initiate treatment (years) 1.3 ± 1.4 1.0 ± 1.5 0.212 1
LED (mg) 730.4 ± 433.4 797.6 ± 414.7 0.177 1
Current Levodopa dose (mg) 674.5 ± 410.9 746.1 ± 387.3 0.710
Depression BDI (M ± SD)
(% with depression)
9.5 ± 6.4
23.6 (n = 13)
11.9 ± 8.6
35.8 (n = 19) 0.287
1
Depression HADS (M ± SD)
(% with depression)
4.9 ± 3.7
20.0 (n = 11)
5.3 ± 3.7
26.4 (n = 14) 0.462
1
Anxiety HADS (M ± SD)
(% with anxiety)
5.7 ± 3.9
29.1 (n = 16)
5.1 ± 3.4
24.5 (n = 13) 0.517
1
Apathy AS (M ± SD)
(% with apathy)
13.2 ± 5.4
49.1 (n = 27)
15.9 ± 5.6
63.5 (n = 33) p < 0.05
1
Fatigue PFS−16 (M ± SD)
(% with fatigue)
2.8 ±0.9
27.3 (n = 15)
3.1 ±1.0
45.3 (n = 24) 0.078
1
Sleep disorders PSQI (M ± SD)
(% with sleep disorders)
6.4 ± 3.3
56.4 (n = 31)
6.2 ± 3.6
52.8 (n = 28) 0.634
1
Excessive daytime sleepiness ESS (M ± SD)
(% with excessive daytime sleepiness)
6.3 ± 4.9
21.8 (n = 12)
7.7 ± 5.3
39.6 (n = 21) 0.167
1
PA-G—Physically Active Patients, PI-G—Physically Inactive Patients, 1 Mann–Whitney U test; 2 chi-squared test.
In the context of the relatively small number of patients treated with piribedil (8 patients of the
whole group) compared to ropinirole, separate analyses of the DA treatment in PI-G and PA-G group
have been omitted.
To determine the relationship between subitems in the total score of each part of the UPDRS scale,
the correlation of coefficients in both groups was calculated. In UPDRS part I, the largest correlation
with total score was found for point 4 (Motivation/Initiative) in both groups, respectively (PA-G r = 0.65;
PI-G r = 0.83); in part II, in PA-G with turning in bed r = 0.75, while in PI-G with walking r = 0.70.
In part III of the UPDRS scale in PA-G, the total score showed the highest correlation with arising from
a chair (r = 0.83), and in PI-G, with agility of the left leg (r = 0.78). In UPDRS part IV in PA-G—with
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symptoms anorexia, nausea or vomiting—r = 0.76, in PI-G, with the presence of “off” periods, r = 0.76,
which was expected.
As potential factors impacting the duration of PA expressed by means of ITMWA, the following
factors were taken into account: age, sex, education, type of medication initiating the therapy and
the current treatment, LED, stage of disease based on the Hoehn–Yahr scale, severity of movement
symptoms in part III of the UPDRS scale, degree of intensification of other Parkinson’s symptoms
based on the UPDRS scale parts I + II + III, anxiety, depression, apathy, fatigue, and sleep disorders.
After analyzing the complete model, using an analysis of linear regression with the method of
backward elimination for each explained variable, the optimum model of factors affecting PA was
created to explain the largest variance of data. Only those models that explained more than 10% of
variability are discussed below.
The complete model explained 12% of the variation in PA and was statistically significant
(R2 = 0.125; F(16.133) = 2.185; p < 0.01). The only significant predictor was starting therapy with DA
(β= 0.420; t= 4.068; p = 0.000), which was associated with a longer duration of moderate PA. While
performing the analysis to determine the best predictors in accordance with the principle of step-wise
approach regression, it was found that six predictors, with the two most significant being beginning
the treatment with DA and the severity of the disease based on the Hoehn–Yahr scale (R2 = 0.171;
F(6.133) = 5.585; p < 0.001), were responsible for 17% of the variability of ITMWA (Table 3).
Another linear regression analysis was carried out to determine the significance of individual
factors in the time spent being sedentary during the day. The complete model with the same predictors
as in the previous analysis, in which the variable to be explained was the time spent sitting, explained
over 13% of the variance and was statistically significant (R2 = 0.135; F(16,130) = 2.267; p < 0.01).
Significant predictors in this model were secondary education, aggravation of movement disorders in
part III of the UPDRS scale and intensification of Parkinson’s symptoms in UPDRS scale, parts I + II + III.
Assuming the best solution (i.e., the model with the highest R2) in accordance with the principle of
step-wise approach regression, it was found that six predictors, the most significant of which were
vocational and secondary education, commencement of treatment with DA and intensification of
mobility symptoms in part III on the UPDRS scale (R2 = 0.193; F(7.130) = 5.429; p < 0.001), were
responsible for over 19% of the variability of daily time spent sitting (in a sedentary way). Less time
spent sitting during the day was observed in the patients with vocational and secondary education,
whose first medication for the treatment of PD was DA and who had more intensified mobility
symptoms (Table 4).
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Table 3. Analysis of backward regression, which determines % of the variability of ITMWA, conditioned by the group of socio-demographic and clinical predictors in
the group of patients with Parkinson’s disease.
Depended Variable Model Predictors R2 F p
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Table 4. Analysis of backward regression, which determines % of variability of time spent in the sedentary position conditioned by the group of socio-demographic
and clinical predictors in the group of patients with Parkinson’s disease.
Depended Variable Model Predictors R2 F p
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As all the models tested, except those presented above, explained less than 10% of the variance
of dependent variables concerning PA, additional analyses of regression (taking into account the
predictors that, in particular models, turned out to be significant) were conducted.
When using the ITMWA as a dependent variable in the model, the predictors were education,
duration of the disease, starting treatment with DA, severity of the disease on the Hoehn–Yahr scale,
and the level of depression symptoms (BDI). The analysis using the method of backward elimination
showed that the optimal model takes into account only three predictors: duration of the disease,
starting treatment with DA, and advancement of the disease on the Hoehn–Yahr scale. This model
was significant and explained more than 15% of the variance (R2 = 0.151; F(3.133) = 8.85; p < 0.001).
However, the only significant predictor turned out to be the start of treatment with DA, which was
connected with increased duration of PA.
In the model where the variable was time spent sitting during the day, the predictors were
education, intensification of mobility symptoms in part III of the UPDRS scale, intensification of
parkinsonian symptoms based on the UPDRS scale parts I + II + III, commencement of DA treatment,
the results of the PFS−16 fatigue scale, and excessive sleepiness (ESS). The analysis conducted with the
method of reverse elimination excluded only the results from the PFS−16 scale, causing the obtained
optimal model to be significant, which explained over 19% of the variance (R2 = 0.195; F(7.130)
= 5.509; p < 0.001). It was found that the patients with secondary and vocational education, who
started treatment with DA and those who had less intense parkinsonian symptoms (UPDRS scale
parts I + II + III), spent less time in a sedentary way during the day (Table 5).
Table 5. Analysis of backward regression, which determines % of the variability of ITMWA and time
spent in the sedentary position in a day in the group of patients with Parkinson’s disease (solely
optimum models with the highest R2 are presented).
Optimal Model Predictors R2 F p
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 14 
 
Table 3. Analysis of backward regression, which determines % of the variability of ITMWA, conditioned by the group of socio-demographic and clinical predictors 
in the group of patients with Parkinson’s disease. 





R2 = 0.125; F(16,133) = 2.185; p < 0.01 
0.007 0.083 0.934 
 Age 0.041 0.452 0.652 
 Professional education 0.141 0.944 0.347 
 Medium education 0.092 0.551 0.582 
 High education 0.206 1.266 0.208 
 Levodopa treatment 0.138 1.493 0.138 
 DA treatment 0.033 0.364 0.717 
 MAOBI treatment −0.047 −0.547 0.585 
 Amantadine treatment 0.010 0.119 0.905 
 Anticholinergic treatment 0.004 0.044 0.965 
 Start of treatment with levodopa 0.157 1.483 0.141 
 Start of treatment with DA 0.420 4.068 0.000 
 LED −0.087 −0.892 0.374 
 Hoehn–Yahr scale −0.210 −1.821 0.071 
 UPDRS part III 0.352 1.181 0.240 
 UPDRS part I + II + III −0.242 −0.785 0.434 
Optimal model  
highest value 
R2 
 Higher Education 
R2 = 0.171; F(6.133) = 5.585; p < 0.001 
0.105 1.261 0.210 
 Levodopa treatment 0.120 1.421 0.158 
 Start of treatment with Levodopa 0.153 1.537 0.127 
 Start of treatment with DA 0.440 4.595 0.000 
 Hoehn–Yahr scale −0.238 −2.283 0.024 
 UPDRS part III 0.144 1.400 0.164 




Duration of the disease
R2 = 0.151; F(3.133) =
8.85; p < 0.001
−0.114 −1.379 0.170
Start of treatment with DA 0.348 4.306 0.000
Hoehn–Yahr scale −0.105 −1.273 0.205
Time spent in the
sedentary position
Medium education
R2 = 0.195; F(7.130) =
5.509; p < 0.001
−0.375 −2.407 0.018
Professional education −0.294 −2.172 0.032
Higher education −0.202 −1.322 0.188
UPDRS part. III −0.589 −1.939 0.055
UPDRS parts I + II + III .787 2.535 0.013
Start of treatment with DA −0.177 −2.190 0.030
ESS 0.147 1.677 0.096
R2—amount of explained variance, F—value of Fisher’s statistics, p—statistical significance,
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 14 
 
Table 3. Analysis of backward regression, which determines % of the variability of ITMWA, conditioned by the group of socio-demographic and clinical predictors 
in the group of patients with Parkinson’s disease. 





R2 = 0.125; F(16,133) = 2.185; p < 0.01 
0.007 0.083 0.934 
 Age 0.041 0.452 0.652 
 Professional education 0.141 0.944 0.347 
 Medium education 0.092 0.551 0.582 
 High education 0.206 1.266 0.208 
 Levodopa treatment 0.138 1.493 0.138 
 DA treatment 0.033 0.364 0.717 
 MAOBI treatment −0.047 −0.547 0.585 
 Amantadine treatment 0.010 0.119 0.905 
 Anticholinergic treatment 0.004 0.044 0.965 
 Start of treatment with levodopa 0.157 1.483 0.141 
 Start of treatment with DA 0.420 4.068 0.000 
 LED −0.087 −0.892 0.374 
 Hoehn–Yahr scale −0.210 −1.821 0.071 
 UPDRS part III 0.352 1.181 0.240 
 UPDRS part I + II + III −0.242 −0.785 0.434 
Optimal model  
highest value 
R2 
 Higher Education 
R2 = 0.171; F(6.133) = 5.585; p < 0.001 
0.105 1.261 0.210 
 Levodopa treatment 0.120 1.421 0.158 
 Start of treatment with Levodopa 0.153 1.537 0.127 
 Start of treatment with DA 0.440 4.595 0.000 
 Hoehn–Yahr scale −0.238 −2.283 0.024 
 UPDRS part III 0.144 1.400 0.164 
R2—amount of explained variance, F—value of Fisher’  stati tics, p—statistical significanc , ϐ—significance of the predictor in the model, t—result of Student’s t-
test. 
significance of the
predictor in the model, t—result of Student’s t-test.
4. Discussion
The overall level of PA in the examined group of patients with PD was low, which is also indicated
by the results of other authors [24]. In terms of NMS, the authors only noted lower apathy in the
group of more physically active patients with PD. The other NMS had no influence on the level of PA.
Moreover, many authors have reported a clear relationship between lower intensity of these symptoms
and PA [25–27]. However, this activity was undertaken within a planned rehabilitation context, and it
was not likely to be replaced with spontaneous PA as a control of NMS. The level of education turned
out to be one of the most important factors affecting participating in PA more often and for a longer
duration and shortening the time during the day spent sitting. Thus, in the model explaining over
15% of the variability in the number of days participating in moderate activity, vocational and higher
J. Clin. Med. 2020, 9, 1296 9 of 12
education were the strongest predictors (p < 0.05). In previous research, the authors related a higher
level of education with participating in health-oriented behaviors, including PA [28].
The results obtained in this study may indicate that patients with higher and secondary education
have a greater awareness of pro-health behaviors and ways to create a healthy lifestyle. PA in this
group may be a continuation of the previously practiced healthy behaviors, including various forms of
PA. In addition, participating in PA in this group may also be a result of a better understanding of
the nature of the disease and non-pharmacological measures to improve health conditions. However,
patients with vocational education may treat PA as a continuation of work-related activity more often.
Additionally, in the model explaining almost 20% of the variability in lack of time spent participating
in PA during the day and secondary and vocational education were strong predictors (p < 0.05). Other
authors also pointed to the importance of education in participating in PA in adults [29] and those
diagnosed with PD [30].
One of the observations of the present study is that increased levels of PA were connected with the
commencement of dopaminergic therapy with DA. In the model explaining nearly 20% of the variability
in time spent sitting during the day, the start of dopaminergic therapy with DA was one of the four
significant explanations (p = 0.030). It is possible that the group of patients starting treatment with DA
have less initial motor dysfunction and experience motor problems that disrupt their activity to a lesser
extent. This may not be associated only with the oligosymptomatic onset of the disease but also with
its mild course. At the same time, it can be assumed that with the appropriate treatment, patients who
report more severe parkinsonian symptoms with greater negative effects on daily functioning receive
the levodopa drug first to initiate the treatment. LED did not affect the level of PA, which was also
reported by other researchers [28]. It should also be taken into account that the reduced risk of motor
complications in patients who use DA but not levodopa at the beginning of their treatment makes
these patients more physically active. This topic requires further research. It has been reported that
DA group drugs (described here as pramipexol) can result in physical exercise dependence, which is
a form of impulse control disorder [31]. The authors also observed such disorders in the course of
ropinirole therapy. However, it should be noted that this type of disorder may manifest in patients
who are currently using the drug and will probably not affect patients who have discontinued DA
therapy. A short assessment of the disorders of impulse control is necessary when excessive PA is
recorded for a patient treated with DA. It is also one of the important reasons for the assessment of
spontaneous PA in patients with PD, with the need to search for ways to best evaluate it and unify the
methods of its examination.
Other strong predictors of the number of days with moderate PA in the model described above
explained over 15% of the variance in this variable, except for education and commencement of treatment
with DA, and included the continuation of treatment with DA in this group. This phenomenon seems
to be connected with the analogous mechanisms related to starting therapy with DA. In turn, in the
model explaining almost 20% of the variability in time spent sitting during the day, except for education
and commencement of treatment with DA, the intensification of Parkinson symptoms assessed by the
sum of the points from part I, II and III of the UPDRS scale was the strongest predictor in this case.
Therefore, with reference to patients with PD, the time spent participating in PA becomes shorter for the
benefit of time spent sitting. The result of the degree of intensification of Parkinson symptoms, both in
terms of mobility and non-mobility, and the limitations in everyday functioning are generally related
to increased disability in the middle-aged period, which has also been noted by other authors [32].
In the case of average weekly PA time, the model accounting for 17% of the variability included the
following significant predictors: starting treatment with DA and lower stage of Hoehn–Yahr disease,
which were associated with a longer duration of physical activity. In turn, among all significant factors
that explained over 19% of the variance in time spent sitting during the day, the following were notable:
vocational and secondary education; lesser total intensification of symptoms from parts I, II and III of
the UPDRS scale and, as previously discussed, commencement of treatment with DA. All of the factors
mentioned above were predicators of less time spent sitting during the day.
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In this study, the importance of the Hoehn–Yahr scale for scientists was confirmed. The subsequent
degrees of the scale reflect the symptoms determining patient mobility. The result of the Hoehn–Yahr
scale also depends on the presence of posture disorders, which are usually connected with distinctive
motor deterioration. The Hoehn–Yahr scale turned out to be more useful in the analysis of the
movement aspects of the disease than Part III of the UPDRS, the paradoxically lower result of which
is associated with a longer time spent sitting. This result may be related to the fact that with lower
intensity of tremors or by slowing down, patients need less time to perform daily activities; hence,
they can spend more time sitting, and this effect disappears when assessing the results of parts I and II
of the UPDRS.
Despite the absence of differences between groups in the results for parts I, III and IV of UPDRS,
it was found that in parts II, III and IV, other items for PA-G and PI-G correlated with the total score of
these assessments. In addition, in part II, the total scores for PA-G and PI-G differed with statistical
significance. The total result in PA-G had the highest correlation with night symptoms—turning in
bed—while in PI-G, the highest correlation was found with gait disturbances, which can limit the
activity of the subjects. However, in the case of PA-G in UPDRS part III, the highest correlation was
shown by arising from a chair, a symptom that only applies to movement initiation, while in PI-G the
highest correlation was found for disorders of the agility left leg, which is a symptom that persists
constantly during activity. On the other hand, in the case of UPDRS part IV in PA-G, it was found
that non-motor treatment complication—anorexia, nausea or vomiting—did not significantly affect
motor activity, while in PI-G, a motor treatment complication—off periods predictable—was found to
unequivocally impair the physical activity taken.
5. Conclusions
The results obtained in this study indicate the association between the selected clinical,
demographic and therapeutic factors and the PA undertaken by PD patients. It may allow for better
identification of the patients threatened by lack of activity and may help increase their activity levels.
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